How to Get Dayvigo (Lemborexant) in North Carolina

What Is Dayvigo and Why Does It Require a Prescription?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for adults with insomnia characterized by difficulty falling or staying asleep. It works by blocking orexin OX1R and OX2R receptors, which suppresses the wakefulness-promoting signals that keep patients alert at night. Because it carries a DEA Schedule IV classification, every dispensed dose must be tied to a valid prescription from a licensed prescriber. Self-purchase is not an option.

The FDA's approval was grounded in two key phase 3 trials. SUNRISE-1 (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep (LPS) versus placebo at six months [1]. SUNRISE-2 (N=949) extended those findings over a 12-month period, confirming durable sleep-onset and sleep-maintenance benefits with no next-morning driving-performance impairment at the 5 mg dose [2]. The FDA label specifies starting at 5 mg, with an option to increase to 10 mg if the lower dose is tolerated but insufficiently effective [3].

A 2023 network meta-analysis published in The Lancet comparing 30 insomnia drugs placed lemborexant among the top agents for both sleep onset and sleep maintenance with a favorable next-day residual sedation profile [4]. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline recommends DORA agents as a first-line pharmacotherapy option for chronic insomnia disorder in adults [5].

Who Can Prescribe Dayvigo in North Carolina?

Any licensed North Carolina prescriber with DEA Schedule IV authority can write a lemborexant prescription. That group includes physicians (MD, DO), nurse practitioners (NP) with full practice authority, and physician assistants (PA) practicing under a supervising physician agreement.

North Carolina granted nurse practitioners full practice authority effective January 1, 2023, under North Carolina General Statutes § 90-18.2. This means a board-certified NP can independently evaluate and prescribe Schedule IV controlled substances, including Dayvigo, without a physician co-signature. PAs may prescribe Schedule IV medications under a written practice agreement that delineates prescriptive authority [6].

A telehealth prescriber must hold an active NC medical license. Out-of-state providers licensed only in another state cannot legally prescribe to an NC patient without a valid NC prescribing license. Verify your provider's NC license status through the NC Medical Board's public directory before your appointment.

Sleep specialists, psychiatrists, primary care physicians, internal medicine physicians, and geriatricians all routinely prescribe Dayvigo. The prescriber does not need a sleep subspecialty certification; a standard evaluation meeting the diagnostic criteria for insomnia disorder in the DSM-5 or ICSD-3 is sufficient [7].

How to Get a Dayvigo Prescription in North Carolina Step by Step

Getting lemborexant in North Carolina follows a straightforward four-step path. Each step is described below with realistic timeframes.

Step 1. Schedule a clinical evaluation (same day to 48 hours). Book an appointment with an NC-licensed provider, either in person or via telehealth. HealthRX's online intake takes under ten minutes. The provider will review your sleep history, current medications (especially CNS depressants), and any history of sleep apnea, narcolepsy, or substance use disorder.

Step 2. The provider completes the evaluation (20 to 30 minutes). The clinician will confirm the insomnia diagnosis, rule out contraindications such as severe hepatic impairment, and select the starting dose (5 mg for most patients; 10 mg may be considered in patients without next-day driving needs). Patients with moderate hepatic impairment should not exceed 5 mg; those with severe impairment should not receive lemborexant at all, per FDA labeling [3].

Step 3. The prescription is sent electronically (within 24 hours). NC permits electronic prescriptions for Schedule IV controlled substances. Your provider will e-prescribe to your preferred NC-licensed pharmacy or to a mail-order pharmacy registered to ship to North Carolina.

Step 4. Insurance or cash-pay processing (1, 5 business days). Most commercial plans require a prior authorization (PA) before dispensing. Your provider's office will submit the PA documentation. Cash-pay prices via GoodRx-type discount programs typically range from $280 to $340 for a 30-count supply as of early 2025.

Telehealth Access to Dayvigo in North Carolina

Telehealth prescribing of Schedule IV controlled substances in North Carolina is permitted without a mandatory in-person visit, provided the prescriber establishes a valid patient-provider relationship through a synchronous audio-video evaluation. This aligns with NC Session Law 2021-180, which codified telehealth prescribing standards post-pandemic.

The Ryan Haight Act of 2008 historically required an in-person examination before prescribing controlled substances via telemedicine. The DEA's 2023 proposed telehealth rules would have re-imposed this requirement after the COVID-19 public health emergency ended, but the DEA's final Special Registrant telemedicine rule extended pandemic-era flexibilities through December 31, 2025, allowing Schedule IV prescribing via telemedicine without a prior in-person visit as long as the prescriber holds a valid DEA registration and the video-audio evaluation meets standards [8]. Confirm your telehealth platform's compliance before booking.

HealthRX providers hold active NC medical licenses and DEA registrations that include Schedule IV authority. A video consultation with an HealthRX clinician satisfies all current NC telehealth prescribing requirements for lemborexant.

A 2022 JAMA Internal Medicine study (N=4,510) found that telehealth-initiated insomnia treatment produced equivalent adherence rates to in-person care at 12-month follow-up, supporting telehealth as a clinically sound pathway for chronic insomnia management [9].

What Labs or Tests Are Needed Before Dayvigo?

Dayvigo does not require routine pre-treatment lab work. The FDA label specifies no mandatory baseline laboratory panel [3]. However, most NC clinicians will order or review recent results in specific clinical scenarios.

A complete hepatic function panel is appropriate when the patient reports a history of liver disease, heavy alcohol use, or takes medications metabolized primarily by CYP3A4, since lemborexant is itself a CYP3A4 substrate. Co-administration of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) is contraindicated; moderate inhibitors (e.g., fluconazole, erythromycin) require dose reduction to 5 mg [3]. The FDA's drug interaction guidance for lemborexant is detailed in the prescribing information on the FDA accessdata portal [10].

If the provider suspects comorbid obstructive sleep apnea, a polysomnogram or home sleep apnea test referral may precede or accompany the prescription. Dayvigo is not contraindicated in mild-to-moderate OSA, but the FDA label advises caution; patients should report any new or worsening respiratory symptoms [3].

A urine drug screen is not universally required but may be ordered by providers following controlled substance prescribing protocols, particularly in patients with a history of substance use disorder. The NC DHHS Controlled Substances Reporting System (CSRS) query is standard practice to check for concurrent Schedule IV or III prescriptions from other providers [11].

Prior Authorization Requirements in North Carolina

Most NC commercial insurers and pharmacy benefit managers classify Dayvigo as a non-preferred brand, requiring prior authorization before dispensing. NC Medicaid does not cover lemborexant for insomnia; the NC Medicaid preferred drug list currently limits coverage of orexin antagonists for type 2 diabetes-related indications, and Dayvigo carries no such indication [12].

A typical NC commercial PA submission for Dayvigo requires the following documentation:

1. Confirmed diagnosis of insomnia disorder (ICD-10 G47.00 or G47.09)
2. Documentation of an adequate trial with at least one generic alternative, commonly zolpidem 5 mg or 10 mg for a minimum of four weeks
3. The clinical rationale for selecting lemborexant, such as next-day impairment with zolpidem or a contraindication to benzodiazepine-related drugs
4. The prescriber's DEA number and NC license number

Blue Cross and Blue Shield of North Carolina, Aetna NC, and UnitedHealthcare NC plans all require steps 1 through 4 as of 2024. Appeals success rates improve substantially when the prescriber includes peer-reviewed evidence; the SUNRISE-1 and SUNRISE-2 publications [1][2] and the AASM guideline statement [5] are appropriate to attach.

The PA process typically takes three to five business days. Urgent appeals can be resolved within 72 hours under NC Department of Insurance prompt-pay rules. Patients can request a bridge supply of up to a 72-hour emergency prescription at the pharmacist's discretion while the PA is pending, though not all NC pharmacies honor this option for Schedule IV agents.

Pharmacy Options for Dayvigo in North Carolina

Dayvigo is commercially manufactured by Eisai and is stocked at most major NC retail pharmacy chains, including CVS, Walgreens, Harris Teeter, Walmart Pharmacy, and Rite Aid locations. Specialty and independent pharmacies also carry it on request. Because it is a Schedule IV controlled substance, NC law requires the pharmacy to verify the prescriber's DEA registration before dispensing.

Mail-order fulfillment is permitted. A 90-day supply can be dispensed by an NC-licensed mail-order pharmacy with a valid e-prescription. Several pharmacy benefit managers, including Express Scripts and OptumRx, require mail-order after the first dispensing for maintenance insomnia therapy; review your plan's formulary.

503A compounding pharmacies in North Carolina are licensed to compound patient-specific preparations, but they cannot legally compound lemborexant. FDA's list of bulk drug substances approved for 503A compounding does not include lemborexant; compounding a copy of a commercially available approved drug without a valid clinical difference is prohibited under 21 U.S.C. § 503A [13]. Any NC 503A pharmacy advertising compounded lemborexant would be operating outside FDA guidelines.

For uninsured patients, Eisai offers the Dayvigo Patient Assistance Program. Patients with household incomes at or below 400% of the federal poverty level may qualify for a free 30-day supply. The application is available through Eisai's NeedyMeds listing and requires proof of income and NC residency [14].

Clinical Efficacy: What the Evidence Shows

The efficacy data for lemborexant are among the strongest in the FDA-approved insomnia drug class. SUNRISE-1 enrolled 1,006 adults with insomnia disorder and randomized them to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 nights. Both lemborexant doses produced statistically significant reductions in subjective sleep onset latency versus placebo (P<0.001), and lemborexant 10 mg outperformed zolpidem ER on objective LPS at night 1 and night 29 as measured by polysomnography [1].

SUNRISE-2 ran for 12 months (N=949) and compared lemborexant 5 mg and 10 mg against placebo. At month 6, subjective wake after sleep onset (sWASO) was reduced by 41.2 minutes in the 10 mg group versus 27.3 minutes in the placebo group (P<0.001) [2]. Discontinuation rates due to adverse events were 3.7% for the 5 mg dose and 5.0% for the 10 mg dose, versus 2.8% for placebo.

A 2021 post-hoc analysis published in Sleep Medicine (N=534 adults aged 65 and older) found that lemborexant reduced subjective sleep onset latency by 27.0 minutes versus placebo in older adults, with no statistically significant next-morning balance impairment at the 5 mg dose, which is particularly relevant for NC's large geriatric population [15]. Falls and next-morning psychomotor impairment are primary concerns in seniors taking hypnotics, and the AASM guideline specifically notes the more favorable safety profile of DORAs over benzodiazepines and Z-drugs in older patients [5].

The FDA's Medication Guide for Dayvigo lists the most common adverse events as somnolence (10% at 10 mg, 7% at 5 mg), headache (6%), and nightmare or abnormal dreams (4%) [3]. Serious adverse events including sleep paralysis and hypnagogic hallucinations were reported in less than 2% of trial participants.

Safety Considerations and Drug Interactions

Lemborexant carries a class-level warning for complex sleep behaviors, including sleepwalking and sleep driving, consistent with all approved hypnotics. Patients should be counseled not to take Dayvigo unless they can dedicate at least seven hours to sleep. Alcohol and other CNS depressants substantially increase sedation risk; concomitant use of opioids with Dayvigo requires a specific risk-benefit discussion per the FDA label's Boxed Warning section on CNS depressants [3].

CYP3A4 drug interactions are the most clinically significant pharmacokinetic concern. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce lemborexant plasma concentrations to potentially sub-therapeutic levels and the combination should be avoided. Patients on moderate CYP3A4 inhibitors, which are common in NC's aging population (e.g., diltiazem, verapamil, fluconazole), should be capped at 5 mg [3][16].

Pregnancy and lactation: Lemborexant is not approved for use in pregnancy. Animal studies showed developmental toxicity at exposures below the maximum recommended human dose. There are no adequate human pregnancy data [3]. The drug's presence in human breast milk is unknown; NC clinicians should advise breastfeeding patients to discuss alternatives with their provider.

Patients should also be entered in the NC Controlled Substances Reporting System at the time of prescribing, and their CSRS profile should be reviewed at every refill visit to identify concurrent controlled substance prescriptions from other providers, consistent with NC DHHS prescriber guidelines [11].

Transferring a Dayvigo Prescription to North Carolina

Patients moving to North Carolina from another state can transfer a Dayvigo prescription under specific conditions. Because lemborexant is a Schedule IV controlled substance, federal DEA regulations (21 C.F.R. § 1306.25) permit a one-time transfer of a Schedule IV prescription between pharmacies in different states, provided both pharmacies are DEA-registered and the prescription has remaining refills [17].

Practically: call the NC pharmacy where you want to fill the prescription and provide the name, phone number, and address of your out-of-state pharmacy. The NC pharmacist will contact the originating pharmacy directly. The original prescription must be voided at the transferring pharmacy upon completion. If your prior prescription has no refills remaining, you will need a new evaluation with an NC-licensed provider before a new prescription can be issued.

Patients with established insomnia diagnoses should bring prior provider notes, medication history, and any sleep study results to their NC intake appointment. This expedites the clinical evaluation and supports the prior authorization documentation if commercial insurance requires a step-therapy trial history.